Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis

Evolving concepts in the treatment of relapsing multiple sclerosis

(2017) Giancarlo Comi et al.   LANCET

Treatment decisions in multiple sclerosis — insights from real-world observational studies

(2017) Maria Trojano et al.   Nature Reviews Neurology

Observational data: Understanding the real MS world

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

(2016) Nils Koch-Henriksen et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Comparative efficacy of fingolimod vs natalizumab

(2016) Laetitia Barbin et al.   NEUROLOGY

Observational data: Understanding the real MS world

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

(2016) Nils Koch-Henriksen et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials

(2016) Georgios Tsivgoulis et al.   PLoS One

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

(2015) Anna He et al.   JAMA Neurology

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

(2013) Stefan Braune et al.   JOURNAL OF NEUROLOGY

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

(2011) J Theodore Phillips et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE